Oppenheimer Asset Management Inc. Sells 845 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Oppenheimer Asset Management Inc. cut its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 6.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,968 shares of the company’s stock after selling 845 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Ionis Pharmaceuticals were worth $777,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 12,856,865 shares of the company’s stock worth $826,311,000 after purchasing an additional 383,350 shares during the period. BlackRock Inc. increased its stake in shares of Ionis Pharmaceuticals by 15.5% in the second quarter. BlackRock Inc. now owns 8,802,576 shares of the company’s stock worth $565,743,000 after purchasing an additional 1,181,004 shares during the period. Invesco Ltd. increased its stake in shares of Ionis Pharmaceuticals by 2,754.9% in the second quarter. Invesco Ltd. now owns 2,271,539 shares of the company’s stock worth $145,992,000 after purchasing an additional 2,191,974 shares during the period. Renaissance Technologies LLC bought a new position in shares of Ionis Pharmaceuticals in the second quarter worth about $112,814,000. Finally, Wells Fargo & Company MN increased its stake in shares of Ionis Pharmaceuticals by 5.9% in the second quarter. Wells Fargo & Company MN now owns 1,076,304 shares of the company’s stock worth $69,174,000 after purchasing an additional 59,667 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the completion of the sale, the chairman now owns 79,634 shares in the company, valued at approximately $5,695,423.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of research firms have recently commented on IONS. Evercore ISI set a $76.00 price objective on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, August 7th. BidaskClub lowered Ionis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 5th. ValuEngine lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. BMO Capital Markets decreased their target price on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 24th. Finally, TheStreet downgraded Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $73.45.

IONS stock opened at $57.06 on Friday. The business’s 50-day simple moving average is $57.99 and its 200 day simple moving average is $64.32. The company has a market cap of $7.64 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 15.24 and a beta of 1.90. Ionis Pharmaceuticals Inc has a twelve month low of $48.27 and a twelve month high of $86.58. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.49. The company had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) EPS. On average, equities research analysts anticipate that Ionis Pharmaceuticals Inc will post 0.25 EPS for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Further Reading: What is an inverted yield curve?

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Leave a Reply

Your email address will not be published. Required fields are marked *

*